Linaclotide

Linaclotide is a 14-amino acid synthetic peptide that acts as an agonist of the guanylate cyclase-C (GC-C) receptor located on the luminal surface of intestinal epithelial cells. Developed by Ironwood Pharmaceuticals and marketed as Linzess (in the US) and Constella (in Europe), linaclotide was approved by the FDA in 2012 for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults.

The mechanism of action involves linaclotide binding to GC-C receptors, which stimulates the production of cyclic guanosine monophosphate (cGMP) inside intestinal epithelial cells. Elevated intracellular cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, leading to secretion of chloride and bicarbonate into the intestinal lumen. This increases intestinal fluid secretion and transit, providing relief from constipation. An active metabolite of linaclotide also acts extracellularly to reduce the firing of visceral pain-sensing nerves, providing the analgesic effect that is particularly important for IBS-C patients.

Clinical trials in the phase 3 program demonstrated that linaclotide significantly improved bowel movement frequency, stool consistency, straining, abdominal pain, bloating, and overall IBS-C symptom severity compared to placebo. The dual mechanism — addressing both constipation and visceral pain — distinguishes linaclotide from simple laxatives and makes it particularly useful for IBS-C, where abdominal pain is a cardinal symptom.

The peptide's structure includes three disulfide bonds that provide resistance to proteolytic degradation in the gastrointestinal tract. Linaclotide acts locally in the intestine with minimal systemic absorption, which contributes to its favorable safety profile. However, diarrhea is the most common side effect, occurring in approximately 20% of patients.